BTMD · biote Corp.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $5.6M | the second quarter of 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 12.6% | the second quarter of 2026 | — |
|
|
|||
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BTMD
this stock
biote Corp.
|
$61.26M | -37.3% | -2.5% | 3.8 | 1.5% |
|
HCA
HCA Healthcare, Inc.
|
$90.71B | -12.1% | +7.1% | 14.1 | 2.6% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$30.50B | -2.9% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.08B | +29.1% | -2.3% | 10.1 | 3.7% |
|
FMS
Fresenius Medical Care AG
|
$12.83B | +5.3% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BTMD | -26.6% | -28.5% | -22.0% | -27.6% | -37.3% |
| SPY | +3.6% | +2.2% | +12.8% | +2.9% | +12.7% |
| vs SPY | -30.2% | -30.8% | -34.8% | -30.4% | -50.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.